Powering the Immune System to Transform Lives

Our Pipeline

A Deep, Broad Pipeline to Address Unmet Patient Need

Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.

Hepatitis Delta

tobevibart + elebsiran

Collaborator:: Alnylam
Treatment Type:: Treatment
Phase:: Phase 2,100%

Learn more about our therapeutic focus on Hepatitis Delta

Hepatitis B

elebsiran + PEG-IFN-α

Collaborator:: Alnylam
Treatment Type:: Treatment
Phase:: Phase 2,100%

tobevibart ± elebsiran ± PEG-IFN-α¹

Collaborator:: Alnylam
Treatment Type:: Treatment
Phase:: Phase 2,100%

elebsiran + TLR8² + PD-1³

Collaborator:: Alnylam / Gilead
Treatment Type:: Treatment
Phase:: Phase 2,100%

Learn more about our therapeutic focus on Hepatitis B

HIV

VIR-1388

Collaborator:: BMGF, NIAID and HVTN**
Treatment Type:: Prevention
Phase:: Phase 1,100%

Cure: mAb combination

Collaborator:: BMGF
Treatment Type:: Treatment
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on HIV

RSV & MPV

VIR-8190*
Preclinical antibody candidates

Treatment Type:: Prevention
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on RSV & MPV

Influenza

VIR-2981 (Influenza A+B)
ADCs

Treatment Type:: Prevention
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on Influenza A

Pre-Cancerous HPV Lesions

VIR-1949

Treatment Type:: Treatment
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on Pre-Cancerous HPV Lesions

COVID-19

VIR-7229

Treatment Type:: Prevention
Phase:: Pre-clinical,100%

Sotrovimab***

Collaborator:: GSK
Treatment Type:: Treatment (Early)
Phase:: Authorized,100%

Learn more about our therapeutic focus on COVID-19

1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols)
2: GS-9688
3: nivolumab
* Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for RSV.
** Bill and Melinda Gates Foundation, National Institute of Allergy and Infectious Diseases, and HIV Vaccine Trials Network.
*** Sotrovimab for early treatment by IV currently has marketing approval, temporary authorization or emergency use authorization in >30 countries. In April 2022, the FDA deauthorized sotrovimab‘s use in all US regions. Commercialized by GSK.
ADCs = Antibody-drug conjugates